The use of the CSF-1R inhibitor PLX3397 effectively suppressed the BNCT-induced circulating M-MDSCs, as well as tumor-infiltrating M-MDSCs and tumor-associated macrophages, leading to an increase in CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.